Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
TrkA receptor inhibitor
DRUG CLASS:
TrkA receptor inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
larotrectinib (189)
entrectinib (178)
GW441756 (1)
KRC-108 (1)
PBI-200 (0)
DCC-2701 (0)
larotrectinib (189)
entrectinib (178)
GW441756 (1)
KRC-108 (1)
PBI-200 (0)
DCC-2701 (0)
›
Associations
(369)
News
Trials
Search handles
@BenjaminBesseMD
@ChristianRolfo
@StephenVLiu
Search handles
@BenjaminBesseMD
@ChristianRolfo
@StephenVLiu
Filter by
Latest
9ms
New case report – successful limb salvage of a child with infantile fibrosarcoma using Larotrectinib @drshubhamsahni @samdoc_mamc https://t.co/g0f4GGrWFh (@ecancer)
9 months ago
Vitrakvi (larotrectinib)
9ms
Fantastic learning programme from @DrEzraCohen ! Updates on #NTRK fusions in #thyroidcancer with a focus on: ✅Treatments such as #entrectinib and #larotrectinib ✅ Histopathology ✅Efficacy and safety of treatment Watch and download the slides here👇 https://t.co/KEY6lBsvUT (@PresOnc_Connect)
9 months ago
Clinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
|
Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
11ms
#ASCO23 | Hall A | Sunday 8am CT Long-term Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer Jessica Lin, MD (@JessicaJLinMD) ➡️ https://t.co/I4j2RKV3WG @ASCO #MGCCatASCO23 (@MGHCancerCenter)
11 months ago
Clinical
|
Vitrakvi (larotrectinib)
11ms
🎙️ In this JCO PO Conversations podcast episode, host @thenasheffect speaks with @alexdrilon about his JCO PO article "Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers" 🎧 Take a listen ➡️ https://t.co/JEuabTW4St (@JCOPO_ASCO)
11 months ago
Clinical
|
Vitrakvi (larotrectinib)
12ms
Dr. @RobertoFerrara_ at #RomeLung23 discusses #NTRK as a viable target in NSCLC with two approved drugs: larotrectinib and entrectinib. Still unraveling primary and acquired resistance but newer agents like repotrectinib showing promise. (@StephenVLiu)
12 months ago
Preclinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Augtyro (repotrectinib)
1year
@DavidHongMD discusses updated findings from an analysis of 3 trials which ultimately led to the approval of #larotrectinib for patients with solid tumors who harbor an #NTRK fusion. #lcsm | @MDAndersonNews https://t.co/k1oP43s5t8 (@TargetedOnc)
1 year ago
Clinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
|
Vitrakvi (larotrectinib)
over1year
@alexdrilon discussed NTRK fusions in solid tumors, collective findings of studies assessing #larotrectinib for the treatment of these fusions, and how to conduct genomic testing to identify patients who might benefit from TRK inhibitor therapy. #lcsm https://t.co/YngHUi76Io (@TargetedOnc)
over 1 year ago
Clinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
|
Vitrakvi (larotrectinib)
over1year
@MGHCancerCenter @MGHBreastOnc CRC extraordinaire Jenny Keenan presents case of TRK inhibitor in MBC pt with NTRK fusion seen in cfDNA. #SABCS22 (@BeverlyMoy)
over 1 year ago
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
over1year
Exciting long term results for TRK inhibition in NTRK fusion #sarcoma - 4 studies 60% ORR with Entrectenib @herbloong 84% ORR - median DOR 43.3m - with Larotrectedin in paediatric & #AYA & adult #sarcoma by Catherine Albert inc infantile fibrosarcoma #CTOSTweeTOS @OncoAlert (@DrLizConnolly)
over 1 year ago
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
almost2years
@BenjaminBesseMD @ASCO #ASCO22 discussed many things about targets in #lungcancer, and about #NTRK resistance and 2nd generation #TRK inhibitors. (@EugeneManley)
almost 2 years ago
NTRK (Neurotrophic receptor tyrosine kinase)
over2years
Join Prof. George Demetri (@DrSarcoma) today as he will provide a high-level overview of the use of TRK inhibition to treat #cancers harboring NTRK fusions, offer expert strategies, clinical pearls, and best practice recommendations. REGISTER NOW➡️https://t.co/TBaUSmrTTS (@ClinicalCareSol)
over 2 years ago
Clinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
over2years
Introducing the next-gen NTRK inhibitors! In 23 pts with NTRK+ solid tumors pretreated with a TRK inhibitor, repotrectinib induced an objective response rate of 43%! When a resistant mutation was identified (n=13), ORR=54%. #Targets21 @NTRKers (@BenjaminBesseMD)
over 2 years ago
Clinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
Augtyro (repotrectinib)
over2years
STARTING SOON! Join Prof. George Demetri @DrSarcoma today as he will provide an overview of the use of TRK inhibition to treat #cancers harboring NTRK fusions, offer expert strategies and best practice recommendations. REGISTER NOW➡️https://t.co/ns3Ioch1DR #oncology #medtwitter (@ClinicalCareSol)
over 2 years ago
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
over3years
Starting Soon! Join Todd Bauer, MD and @alexdrilon today at 11:30AM ET for a discussion on the rationale for screening patients with #lungcancer for #NTRK fusions and integrating #TRK inhibitors into their treatment https://t.co/0FbJwOH2hf (@CCO_Education)
over 3 years ago
Clinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
over3years
Learn about the diagnostic principles for #NTRK gene fusions and hear the latest clinical evidence for TRK inhibitors in this new #CME activity featuring Drs. George D. Demetri (@DrSarcoma), Alexander Drilon (@alexdrilon), and Brian Rubin https://t.co/C1hyjJ5gk0 (@PeerView)
over 3 years ago
Clinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
over3years
Learn about the diagnostic principles for #NTRK gene fusions and hear the latest clinical evidence for TRK inhibitors in this new #CME activity featuring Drs. George D. Demetri (@DrSarcoma), Alexander Drilon (@alexdrilon), and Brian Rubin https://t.co/C1hyjJ5gk0 (@PeerView)
over 3 years ago
Clinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
almost4years
Complimentary Webinar: Advances in TRK Inhibitor Therapy and #NTRK Fusion Testing Tomorrow, July 15 @ 12:00 PM ET. Register for free here: https://t.co/P1hEVCr1d7 @CCO_Education @pashtoonkasi @alexdrilon @DrSarcoma Looking forward to it!! (@NTRKers)
almost 4 years ago
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
almost4years
Save the date for this TRK Inhibitor Therapy and NTRK Fusion Testing Webinar! July 10th, 2020. Register here: https://t.co/r3wOPJ4Chw @CCO_Education @alexdrilon @DrSarcoma @pashtoonkasi (@NTRKers)
almost 4 years ago
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
over5years
Entrectinib in NTRK and ROS1 fusión positive Metastatic Pancreatic Cancer, a new promising therapeutic opportunity, our experience published at JCO Precision Oncology @GarridoLagunaMD @ASCOPost @ASCO @JCO_ASCO https://t.co/Rj0WlpXpqP (@ChristianRolfo)
over 5 years ago
Rozlytrek (entrectinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login